Febuxostat

Generic Name
Febuxostat
Brand Names
Adenuric, Uloric, Febuxostat Viatris (previously Febuxostat Mylan), Febuxostat Krka
Drug Type
Small Molecule
Chemical Formula
C16H16N2O3S
CAS Number
144060-53-7
Unique Ingredient Identifier
101V0R1N2E
Background

Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate r...

Indication

Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricem...

Associated Conditions
Chronic, symptomatic Hyperuricemia
Associated Therapies
-
Clinical Trials
Related News

The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina

First Posted Date
2013-01-09
Last Posted Date
2016-04-13
Lead Sponsor
Takeda
Target Recruit Count
30
Registration Number
NCT01763996

A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout

Phase 3
Completed
Conditions
Gout
Interventions
Drug: Allopurinol
Drug: febuxostat
First Posted Date
2012-11-29
Last Posted Date
2014-10-29
Lead Sponsor
Astellas Pharma Taiwan, Inc.
Target Recruit Count
109
Registration Number
NCT01736514

Febuxostat for Tumor Lysis Syndrome Prevention in Hematologic Malignancies

Phase 3
Completed
Conditions
Tumor Lysis Syndrome
Interventions
Drug: Febuxostat
Drug: Allopurinol
First Posted Date
2012-11-09
Last Posted Date
2014-11-02
Lead Sponsor
Menarini Group
Target Recruit Count
346
Registration Number
NCT01724528

A Proof-of-Concept Study of AC-201 to Prevent Gout Flares

Phase 2
Completed
Conditions
Gout Flares
Interventions
Drug: Placebo
Drug: AC-201
Drug: Febuxostat
First Posted Date
2012-10-23
Last Posted Date
2018-05-22
Lead Sponsor
TWi Biotechnology, Inc.
Target Recruit Count
82
Registration Number
NCT01712204
Locations
🇨🇳

Veterans General Hospital, Taipei, Taiwan

The Blood Pressure Effects of Febuxostat in Patients Previously Treated With Allopurinol: A Pilot Study

Not Applicable
Terminated
Conditions
Gout
Blood Pressure
Interventions
Drug: febuxostat
First Posted Date
2012-10-05
Last Posted Date
2018-01-12
Lead Sponsor
University of Mississippi Medical Center
Target Recruit Count
1
Registration Number
NCT01701622
Locations
🇺🇸

University of Mississippi Medical Center General Medicine/Hypertension and Family Medicine Clinics, Jackson, Mississippi, United States

Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome

Phase 4
Completed
Conditions
Gout
Interventions
Drug: Febuxostat
First Posted Date
2012-07-31
Last Posted Date
2023-03-14
Lead Sponsor
University of Texas Southwestern Medical Center
Target Recruit Count
24
Registration Number
NCT01654276
Locations
🇺🇸

UT Southwestern Medical Center, Dallas, Texas, United States

Clinical Study to Evaluate the Pharmacokinetic Characteristics Between TMX-67 and Feburic® in Healthy Volunteers

Phase 1
Completed
Conditions
Gout
Interventions
Drug: Feburic®
Drug: TMX-67
First Posted Date
2012-03-27
Last Posted Date
2012-03-27
Lead Sponsor
SK Chemicals Co., Ltd.
Target Recruit Count
30
Registration Number
NCT01563432
Locations
🇰🇷

Korea University Anam Hospital, Seoul, Korea, Republic of

Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina

Phase 2
Terminated
Conditions
Angina
Interventions
Drug: Febuxostat
Drug: Placebo
First Posted Date
2012-03-09
Last Posted Date
2013-12-20
Lead Sponsor
Takeda
Target Recruit Count
1
Registration Number
NCT01549977

Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat

First Posted Date
2012-01-16
Last Posted Date
2016-05-26
Lead Sponsor
Ardea Biosciences, Inc.
Target Recruit Count
330
Registration Number
NCT01510769

Effect of Febuxostat on Blood Pressure

Phase 2
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
Drug: Febuxostat
First Posted Date
2011-12-21
Last Posted Date
2015-08-31
Lead Sponsor
Takeda
Target Recruit Count
121
Registration Number
NCT01496469
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy